Raymond James & Associates Amgen Inc Call Options Transaction History

Raymond James & Associates

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 Apr 14, 2023	BUY	$225.79 - $275.2 $1.92 Million - $2.34 Million	8,500 New	8,500 $2.05 Million
Q2 2021 Aug 11, 2021	SELL	$233.58 - $259.14 $10.8 Million - $12 Million	-46,400 Reduced 73.89%	16,400 $91,000
Q1 2021 May 14, 2021	BUY	$221.91 - $258.6 $11 Million - $12.8 Million	49,600 Added 375.76%	62,800 $159,000
Q4 2020 Feb 12, 2021	SELL	$216.38 - $257.67 $151,466 - $180,369	-700 Reduced 5.04%	13,200 $15,000
Q3 2020 Nov 04, 2020	SELL	$234.65 - $260.95 $117,325 - $130,475	-500 Reduced 3.47%	13,900 $12,000
Q2 2020 Jul 28, 2020	SELL	$197.81 - $242.74 $316,496 - $388,384	-1,600 Reduced 10.0%	14,400 $49,000
Q1 2020 Apr 21, 2020	SELL	$182.24 - $241.7 $3.28 Million - $4.35 Million	-18,000 Reduced 52.94%	16,000 $10,000
Q4 2019 Feb 12, 2020	SELL	$189.21 - $243.2 $208,131 - $267,520	-1,100 Reduced 3.13%	34,000 $197,000
Q1 2019 May 06, 2019	BUY	$180.87 - $203.88 $705,393 - $795,132	3,900 Added 12.5%	35,100 $7,000
Q4 2018 Feb 11, 2019	SELL	$178.4 - $208.25 $142,720 - $166,600	-800 Reduced 2.5%	31,200 $19,000
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $111,174 - $125,333	-600 Reduced 1.84%	32,000 $16,000
Q2 2018 Aug 14, 2018	BUY	$166.05 - $186.51 $3.65 Million - $4.1 Million	22,000 Added 207.55%	32,600 $7,000
Q2 2017 Aug 14, 2017	BUY	N/A	10,600	10,600 $90,000

3,125

409M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.